Pediatrics, Hematology-oncology
-
-
Administers Grant
-
2018 ALSF Million Mile Grant
-
A Multi-Center Phase III, Randomized, Open-Label Trial of Vigil (bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in combination with Irinotecan and Temozolomide as a Second-Line Regimen for Ewing's Sarcoma (CL-PTL-130)
-
A NOVEL ROLE FOR THE CRM1 NUCLEAR EXPORT RECEPTOR IN LEUKEMOGENESIS: MECHANISMS AND TARGETING
-
A Novel Hippo-Notch axis controlling embryonal rhabdomyosarcoma tumorigenesis
-
A Novel Mechanism for Drugs Targeting the CRM1 Nuclear Export Protein in Leukemia
-
A Novel Role for the CRM1 in Pediatric Leukemias: Mechanisms and Targeting
-
A Phase 2, Multicenter, Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab, with or without Hydroxyurea/Hydroxycarbamide, in Sequential, Descending Age Groups of Pediatric Sickle Cell Disease Patients with Vaso-Occl
-
A Phase 3 Study of Eltrombopag vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children
-
A Phase 3b, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects with Immun
-
A Phase I trial of pomalidomide for children with recurrent, progressive or refractory CNS tumors
-
A Phase III Study of 131I Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
-
A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination with 5-Azacytidine in Patients with Recurrent, Resectable Osteosarcoma
-
A phase II, open-label, non-controlled, intrapatient dose escalation study to characterize the pharmacokinetics after oral administration of eltrombopag in pediatric patients with refractory, relapsed or treatment naiive severe aplastic anemia or rec
-
A randomized, open-label, active controlled, safety and extrapolated efficacy study in pediatric subjects requiring anticoagulation for the treatment of a venous thromboembolic event
-
AIDS MALIGNANCY CONSORTIUM
-
ALTE15N2 STUDY
-
Acid Sphingomyelinase Activation in Apoptosis
-
Blood Based Biomarkers for Minimal Residual Disease Detection in Pediatric Sarcomas
-
COG WORK ORDER: (PROJECT: EVERYCHILD (APEC14B1) PCR - COG FOUNDATION
-
COG WORK ORDER: (PROJECT: PEDIATRIC MATCH (APEC1621SC) PCR - COG FOUNDATION
-
COG WORK ORDER: BIQSFP AALL1131
-
COG Work Order AALL07P1--Millennium Pharmaceuticals, Inc.
-
COG Work Order AAML: 1031--Millennium Pharmaceuticals, Inc.
-
COG Work Order: AALL1131: Ph III Clofarabine in High Risk B ALL
-
COMMITTEE LEADERSHIP: NIH National Clinical Trials Network (NCTN) Grant
-
Collection And Storage Centers For Clinical Research...
-
Cyclophosphamide Resistance In Medulloblastoma
-
Defining A Role for the CRM1 Nuclear Export Protein in Pediatric Leukemias
-
Defining and targeting the molecular vulnerabilities of the PAX3-FOXO1 protein in rhabdomyosarcoma
-
Development of peptide vaccine for diffuse intrinsic pontine glioma
-
Dissecting the role of injury is sarcoma formation
-
Dissecting the role of injury is sarcoma formation
-
Effect Of Swainsonine On Human Bone Marrow Stem Cells Trea
-
Effect Of Swainsonine On Human Bone Marrow Stem Cells Trea
-
Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma
-
Examine KPT330 in Murine Leukemia Models
-
Expansion of the AYA Oncology Initiative at Duke University
-
Faces of Research 2020
-
Gamete Preservation in Males Receiving Gametotoxic Chemotherapy
-
Gluathione Modulation Of Alkylators In Medulloblastoma
-
Glutathione Modulation Of Alkylators In Medulloblastoma
-
ICON 1
-
ITP-APPS (Immune ThrombocytoPenia Association of Platelet Parameters Study)
-
Identification and validation of the PAX3-FOXO1 protein interactome
-
Implementing Family Psychosocial Risk Screening for Pediatric Health Equity
-
Investigating co-activator TAZ as a regulator of PAX3-FOXO1, cancer cell stemness, and chemoresistance in fusion-positive rhabdomyosarcoma
-
Investigating the role of Hippo/MST kinases in alveolar rhabdomyosarcoma cancer cell stemness
-
Investigating the role of the transcriptional coactivator TAZ in alveolar rhabdomyosarcoma
-
MAIN STUDY: Developing Evidence-Based Crieteria for Initiating Treatment fo NF1-OPG.
-
Mechanisms of Leukemogenic Transformations by MLL-CALM
-
Melphalan Cytotoxicity And Resistance In Medulloblastoma
-
Molecular Modeling of Pediatric Skeletal Muscle Tumors
-
NCI Community Oncology Research Program (NCORP) Research Base Grant
-
NIH COG Pediatric Early Phase Clinical Trial Network Grant (PEP-CTN)
-
NPFC Sunshine Project
-
Neurobiology And Rational Therapy Of Human Medulloblasto
-
Neurobiology And Rational Therapy Of Human Medulloblastoma
-
Novel regulators of checkpoint adaptation in fusion-positive rhabdomyosarcoma
-
Novel vulnerabilities within PAX3-FOXO1 transcriptional programming for fusion-positive rhabdomyosarcoma
-
PBTC-029
-
PKD Natural Study
-
PROTOCOL AG348-C-008
Pyruvate Kinase Deficiency Global Longitudinal Registry
-
Pediatric Brain Tumor Consortium
-
Pediatric Hydroxyurea Phase III Clinical Trial (Baby Hug): Follow-Up Observational Study II
-
Pediatric Oncology Group
-
Pediatric Oncology Group Studies
-
Pediatric Oncology Group Studies
-
Pediatric Oncology Group Studies
-
Pediatric Oncology Group Studies
-
Pediatric Oncology Group Studies
-
Pediatric Oncology Group Studies
-
Per Case Reimbursement : NIH National Clinical Trials Network (NCTN)
-
Phase I Trial Of 06-Benzylguanine Plus Bcnu In Glioma
-
Phase I study of PD-0332991 for pediatric patiens with retinoblastoma protein (RB)-positive recurrent or refractory central nervous system (CNS) tumors.
-
Pratt Cares Program
-
Project: One Time EOY, Integrated BIQSFP AAML1031- Echocardiogram Reports and Images
-
Prospective validation of a venous thrombosis risk assessment model in critically ill children from the CHAT Registry (CHAT 1901)
-
Role of MST/Hippo kinase inactivation in driving fusion-positive rhabdomyosarcoma
-
Role of the macro lncRNA KCNQ1OT1 in embryonal rhabdomyosarcoma tumorigenesis
-
Role of the macro lncRNA KCNQ1OT1 in embryonal rhabdomyosarcoma tumorigenesis
-
SJMB12: A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
-
STUDY CHAIR: NIH National Clinical Trials Network (NCTN) Grant
-
Specimen Banking Supplements
-
St. Baldrick's Summer Fellow Grant
-
TCD With Transfusions Changing to Hydroxyurea (TWITCH) Closeout
-
TRIAL OF TOPICAL VT30 IN SUBJECTS WITH VENOUS, LYMPHATIC OR MIXED MALFORMATIONS ASSOCIATED WITH PIK3CA OR TEK GENETIC MUTATIONS
-
Targeting the Hippo pathway in Ras-driven rhabdomyosarcoma
-
The role of H3K27M-induced aberrant PRC2 activity in brainstem gliomagenesis
-
The role of MEST (mesoderm specific transcript) in rhabdomyosarcoma
-
The role of MST1 in non-canonical Hippo signaling in rhabdomyosarcoma
-
The secreted protein SFRP3 as a therapeutic target in rhabdomyosarcoma
-
Transplant Centers For Clinical Research On
-
Validating a mouse model of rhabdomyosarcoma
-
Visual Field Outcomes in Pediatric Patients with NF1-associated Optic Pathway Gliomas
-
Workload Intensity NIH National Clinical Trials Network (NCTN)